Showing 8,941 - 8,960 results of 100,843 for search '(( 5 mean decrease ) OR ( 5 ((((point decrease) OR (fold decrease))) OR (a decrease)) ))', query time: 1.16s Refine Results
  1. 8941

    Antimycin A treatment decreases respiratory internal rotenone-insensitive NADH oxidation capacity in potato leaves-4 by Daniela A Geisler (70613)

    Published 2011
    “…Black columns, leaves sprayed with 10 μM antimycin A. Transcript abundance is shown for 1 (A), TC54504 (B) and the 28.5 kDa subunit of complex I (C). …”
  2. 8942

    Additional file 5 of Organization of self-advantageous niche by neural stem/progenitor cells during development via autocrine VEGF-A under hypoxia by Taichi Kashiwagi (2430256)

    Published 2023
    “…NeuN+ neurons were significantly decreased by the hypoxic condition (Mean ± SEM, n = 4, *** p = 0.00028. …”
  3. 8943
  4. 8944
  5. 8945

    Table_1_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

    Published 2019
    “…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”
  6. 8946

    Table_2_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

    Published 2019
    “…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”
  7. 8947

    Table_2_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

    Published 2022
    “…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”
  8. 8948

    Table_1_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

    Published 2022
    “…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”
  9. 8949
  10. 8950
  11. 8951
  12. 8952
  13. 8953
  14. 8954
  15. 8955
  16. 8956

    Supplementary Material for: 3,4-Methylenedioxymethamphetamine (Ecstasy) Decreases Inflammation and Airway Reactivity in a Murine Model of Asthma by Stankevicius D. (4130146)

    Published 2012
    “…We also showed that MDMA decreased expression of both Th2-like cytokines (IL-4, IL-5 and IL-10) and adhesion molecules (L-selectin). …”
  17. 8957
  18. 8958

    <i>C. burnetii</i> utilizes α<sub>V</sub>β<sub>3</sub> integrin for uptake in a cholesterol-dependent manner. by Stacey D. Gilk (208034)

    Published 2013
    “…When +cholesterol cells were pre-incubated with vitronectin, the major ligand for a α<sub>V</sub>β<sub>3</sub> integrin, <i>C. burnetii</i> entry decreased by 66% (p = 0.001) and 71% (p<0.0001) as compared to pre-incubation with fibronectin or BSA, respectively. …”
  19. 8959
  20. 8960